Outcome Assessment of Patients of Non-CF Bronchiectasis Admitted with ARF and Managed with NIV as a Primary Mode of Ventilatory Support: An Analytical Observational Study

对以无创通气为主要通气方式的非囊性纤维化支气管扩张患者急性呼吸衰竭入院治疗的预后进行评估:一项分析观察研究

阅读:1

Abstract

INTRODUCTION: Non-cystic fibrosis bronchiectasis is a progressive condition generally associated with chronic bacterial infections and characterized by irreversible destruction and dilation of the airways. [1] The clinical course of individuals with non-cystic fibrosis bronchiectasis is variable, with a significant proportion of patients developing transient exacerbation leading to severe acute respiratory failure (ARF) and requiring ventilatory support. [2] Although the use of NIV in bronchiectasis exacerbations may appear attractive as it can reduce ICU stay, its failure rate exceeds 25%. [3] At the same time, subsequent application of invasive mechanical ventilation, which is associated with a mortality rate of 19 –35% and prolonged ICU stay, appears problematic. [4] OBJECTIVE: The purpose of the present study was to assess the outcome of patients of non-CF bronchiectasis admitted to our institute with ARF and managed with NIV as a primary mode of ventilatory support. We also compared various physiological and clinical parameter between NIV and mechanical ventilation. METHODS: The present study was conducted in the Department of emergency and Critical Care (Trauma and Emergency), IGIMS, Patna, Bihar, India for one year. There were a total of 250 patients with bronchiectasis who were admitted during the above specified period. Among these, 130 patients were admitted with ARF. Totally, 120 patients who required either NIV or IMV. RESULTS: The most common etiology of bronchiectasis was post-tuberculosis (66.66%) followed by idiopathic (16%), ABPA (11.12%), and immunodeficiency (5.55%). NIV was initiated as first line of ventilator support for 90 patients. Among these, 60(66.66%) were managed successfully with NIV. 30 (33.34%) patients failed NIV and required endotracheal intubation during the hospital stay. DISCUSSION /CONCLUSION: Our results suggest that utility of NIV should to be assessed in well-designed prospective studies for ARF in non-CF bronchiectasis patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。